The ground seems to be ready for a defense for humans against the coronavirus pandemic. Moderna Inc.’s vaccine candidate protected 16 monkeys in a trial. Its result in 30,000 humans is awaited, reported livemint.
Two injections of the vaccine protected against heavy exposure to the virus at two different levels of dosage, Moderna said in findings published on Tuesday in the New England Journal of Medicine, reported livemint.
The results on primates
The results, if they hold up in humans, suggest that the vaccine may be able to protect against Covid-19 in both the upper and lower airways, reported livemint quoting the study.
Phase 3 trial to determine the safety and efficacy of the vaccine will begin producing data in November or December. The U.S. government is providing $955 million to help fund the vaccine’s development.
Moderna Inc is planning to price its coronavirus vaccine at $50 to $60 per course, which is $11 more than another vaccine from Pfizer Inc and BioNTech, livemint quoted Financial Times as reporting on Tuesday, citing unnamed sources.
New Delhi: A fourth batch of Indian nationals deported from the US arrived at Indira… Read More
Berhampur: Rushikulya river mouth in Odisha’s Ganjam district has emerged as a major rookery for… Read More
Delhi/Mumbai: Twin tragedies in Delhi and Mumbai claimed the lives of a pair of 18-month-old… Read More
Jajpur: A total of 894 ineligible people fraudulently received benefits under an old-age pension scheme… Read More
Bhubaneswar: The International Conference on Recent Advances in Nanomedicine brought together more than 500 participants,… Read More
New Delhi: In a recent statement that has stirred political conversations, Shashi Tharoor reaffirmed his… Read More
This website uses cookies.
